{"brief_title": "A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors", "brief_summary": "This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.", "condition": ["Neoplasms"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["carboplatin + irinotecan", "irinotecan"], "description": ["Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.", "Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6."], "arm_group_label": ["Arm A", "Arm B"], "other_name": ["Paraplatin"], "criteria": "- children 1-21 years of age - confirmed diagnosis of measurable solid tumor, including brain tumor, which has progressed on or after standard therapy, or for which no effective standard therapy is known - at least 4 weeks since last dose of immunotherapy, radiotherapy, or chemotherapy - no more than 3 prior chemotherapies - no symptomatic brain metastases", "gender": "All", "minimum_age": "1 Year", "maximum_age": "21 Years", "healthy_volunteers": "No", "keyword": "unspecified childhood solid tumor, protocol specific", "mesh_term": ["Irinotecan", "Carboplatin", "Camptothecin"], "id": "NCT00057473"}